Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (51-60 of 274) with videos related to

Pageof 28
Sort By:
Cureus|December 1, 2025
Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell TransplantationSanjay Muttineni, Sasya Dronavalli, Sharmilan Thanendrarajan, et al.
Blood Advances|July 6, 2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman diseaseFrits van Rhee, Adam Rosenthal, Karan Kanhai, et al.
Haematologica|August 30, 2008
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot, Bart Barlogie, Maurizio Zangari, et al.
British Journal of Haematology|March 29, 2008
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1Maurizio Zangari, Frits van Rhee, Elias Anaissie, et al.
Clinical Hematology International|September 21, 2022
Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United StatesSamer Al Hadidi, Deepa Dongarwar, Hamisu Salihu, et al.
Plos One|May 12, 2026
Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH resultsAnwar Rjoop, Ivette Perez, Daoud O Al Aruri, et al.
Genes, Chromosomes & Cancer|March 19, 2014
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genesErming Tian, Jeffrey R Sawyer, Christoph J Heuck, et al.
The Lancet. Haematology|February 7, 2020
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trialsFrits van Rhee, Corey Casper, Peter M Voorhees, et al.
Clinical Hematology International|February 3, 2023
Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple MyelomaSamer Al Hadidi, Deepa Dongarwar, Carolina Schinke, et al.
American Journal of Hematology|October 23, 2023
Siltuximab administration results in spurious IL-6 elevation in peripheral bloodNatalie A Mango, Sheila K Pierson, Mateo Sarmiento Bustamante, et al.
Pageof 28

Showing results (51-60 of 274) with videos related to

Sort By:
Pageof 28
Cureus|December 1, 2025
Disseminated Bartonella henselae Infection in a Patient With Relapsed/Refractory Multiple Myeloma Following Autologous Stem Cell TransplantationSanjay Muttineni, Sasya Dronavalli, Sharmilan Thanendrarajan, et al.
Blood Advances|July 6, 2022
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman diseaseFrits van Rhee, Adam Rosenthal, Karan Kanhai, et al.
Haematologica|August 30, 2008
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapyGuido Tricot, Bart Barlogie, Maurizio Zangari, et al.
British Journal of Haematology|March 29, 2008
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1Maurizio Zangari, Frits van Rhee, Elias Anaissie, et al.
Clinical Hematology International|September 21, 2022
Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United StatesSamer Al Hadidi, Deepa Dongarwar, Hamisu Salihu, et al.
Plos One|May 12, 2026
Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH resultsAnwar Rjoop, Ivette Perez, Daoud O Al Aruri, et al.
Genes, Chromosomes & Cancer|March 19, 2014
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genesErming Tian, Jeffrey R Sawyer, Christoph J Heuck, et al.
The Lancet. Haematology|February 7, 2020
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trialsFrits van Rhee, Corey Casper, Peter M Voorhees, et al.
Clinical Hematology International|February 3, 2023
Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple MyelomaSamer Al Hadidi, Deepa Dongarwar, Carolina Schinke, et al.
American Journal of Hematology|October 23, 2023
Siltuximab administration results in spurious IL-6 elevation in peripheral bloodNatalie A Mango, Sheila K Pierson, Mateo Sarmiento Bustamante, et al.
Pageof 28